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Tetracycline-
Resistant Vibrio 
cholerae O1, 
Kolkata, India
To the Editor: Cholera, caused 
by toxigenic strains of Vibrio cholerae 
O1 or O139, continues to be a major 
cause of illness and death, particularly 
in developing countries. Treatment 
consists of early administration of 
rehydration therapy with appropriate 
oral or intravenous ﬂ  uids. The World 
Health Organization recommends 
antimicrobial drug treatment 
for severely dehydrated patients 
with suspected cholera because it 
substantially shortens the duration 
of diarrhea by reducing the volume 
of watery stools, decreases ﬂ  uid 
requirements, and limits transmission 
by decreasing fecal excretion of V. 
cholerae (1). The progressive increase 
in resistance to multiple drugs 
among strains causing clinical cases 
of cholera in developing countries 
is becoming a serious concern. We 
report the emergence of tetracycline-
resistant  V. cholerae O1 in a well-
deﬁ  ned population in Kolkata, India, 
during 2007–2009.
During a 6-year surveillance 
period (2004–2009), we conducted a 
prospective, community-based study 
at an impoverished urban site in 
Kolkata. The goals of the study were 
to estimate the prevalence of cholera, 
describe its epidemiology, and identify 
potential risk factors that could be 
addressed by public health strategies. 
Rectal swabs samples from patient 
with diarrhea were obtained, placed 
in Cary-Blair transport medium, and 
transported to the laboratory where 
they were processed for isolation 
and identiﬁ  cation  of  Vibrio spp. 
Specimens were plated directly onto 
thiosulphate citrate bile salt sucrose 
agar (Eiken Chemical Company, 
Tokyo, Japan). The specimens were 
plated directly onto thiosulfate citrate 
bile salt sucrose agar. They were then 
incubated in alkaline peptone water 
(pH 8.6) for 6–8 h at 37°C and then 
plated onto the agar. After overnight 
incubation at 37°C, suspected 
colonies were tested biochemically 
and conﬁ  rmed by slide agglutination 
with polyvalent O1 and monovalent 
Ogawa and Inaba antiserum (Difco 
Laboratories, Detroit, MI, USA). 
Antimicrobial drug susceptibility 
testing was performed by using the 
disk diffusion technique on Mueller-
Hinton agar (Difco Laboratories) with 
commercial disks (Oxoid, Cambridge, 
UK) and appropriate control strains 
(2). The MIC of tetracycline was 
determined with 101 randomly 
selected strains by Etest (AB 
Biodisk, Solna, Sweden) following 
manufacturer’s instructions.
During the 2004–2009 sur-
veillance period, we isolated 809 V. 
cholerae O1 organisms, among which 
624 (77%) were Ogawa and 185 
(23%) were Inaba serotypes. The latter 
became the predominant serotype only 
in 2006. In 2007, a sudden upsurge 
in tetracycline resistance was noted 
among  V. cholerae isolates, from 
1% in 2004 to 76% in 2007 before 
decreasing to ≈50% in 2009. An 
increase in resistance to furazolidone 
and tr  imethoprim/sulfamethoxazole 
was also observed during the same 
period. Of the strains that were 
resistant to tetracycline, 99% were 
also resistant to furazolidone and 
trimethoprim/sulfamethoxazole (on-
line Appendix Figure, www.cdc.gov/
EID/content/17/3/568-appF.htm). 
Among the tetracycline-resistant 
isolates (101 randomly selected 
strains), 43% had high-level resistance 
(MIC >16 μg/mL). In addition, 57% of 
V. cholerae O1 organisms had reduced 
susceptibility (i.e., MICs ranged from 
8 μg/mL to 16 μg/mL). 
Tetracycline is the drug of choice 
for treating cholera (1); however, 
during the 6-year period, we observed 
the emergence of tetracycline 
resistance among V. cholerae O1 
isolates and a sudden upsurge in such 
resistance in 2007 when 76% of the 
isolates were resistant. Tetracycline 
resistance was also reported by Mhalu 
et al. (3), from an epidemic of cholera 
in Tanzania, where 76% of isolates 
were found to be resistant after 5 
months of extensive use of this drug for 
treatment and prophylaxis. In a similar 
situation, the extensive prophylactic 
use of tetracycline triggered the rapid 
emergence and spread of tetracycline-
resistant strains in Madagascar 
(4). Tetracycline is not used for 
prophylaxis in Kolkata, a known 
cholera-endemic area. Nonetheless, 
the emergence of resistant strains in 
our study area is not surprising because 
similar tetracycline-resistant strains 
of  V. cholerae have been reported 
in Bangladesh (5), in Mozambique 
(6), and in another study of Kolkata 
(7). Notably, tetracycline-resistant V. 
cholerae O1 strains have also been 
responsible for major epidemics in 
Latin America, Tanzania, Bangladesh, 
and Zaire (8). 
In our study, resistance to 
tetracycline among V. cholerae O1 
isolates was <10% during 2004–
2006. The reasons for the sudden 
rise of resistant strains in 2007 and 
their continued persistence are still 
unclear. Detailed molecular studies 
are underway to ﬁ  nd the explanation. 
Alternative drugs, such as the newer 
ﬂ   uoroquinolones, possess excellent 
activity against V. cholerae O1 and 
O139 serogroups. However, increased 
resistance to newer ﬂ  uoroquinolones, 
such as ciproﬂ  oxacin and norﬂ  oxacin, 
among V. cholerae strains belonging 
to O1 serogroup has also been 
reported (9). 
Resistance to commonly used 
antimicrobial drugs represents a 
critical public health problem because 
it complicates treatment and may 
result in longer hospital stays for 
patients. In addition, most of the 
population in developing countries 
cannot afford the newer and more 
expensive drugs. Our ﬁ  ndings 
emphasize the need for continued 
568  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011LETTERS
surveillance of antimicrobial drug 
susceptibility patterns of V. cholerae. 
Providing early information on 
antimicrobial drug susceptibility to 
practitioners in affected areas will 
lessen the illness and death from this 
devastating disease. 
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Neisseria 
meningitidis Strain 
of Unknown 
Serogroup, China 
To the Editor:  Neisseria 
meningitidis is a major public health 
hazard in many parts of the world. 
This organism is classiﬁ   ed into 13 
serogroups, and most meningococcal 
disease is caused by strains that 
express 1 of the 5 types of capsular 
polysaccharides (A, B, C, Y, and 
W135). In the natural reservoir of 
the human nasopharynx, strains of N. 
meningitidis that do not ﬁ  t into 1 of 
the 13 serogroups and are presumably 
unencapsulated are common. By 
contrast, rare meningococcal diseases 
are caused by these nonserogroupable 
strains. In this article, we describe 
a case of N. meningitidis infection 
caused by a nonserogroupable strain 
in the People’s Republic of China and 
the genotype characteristics of this 
strain.
The patient was a 6-month-old 
boy who was admitted to a local 
hospital in Beijing in May 2009. The 
infection started suddenly with high 
fever (39°C). N. meningitidis infection 
was conﬁ   rmed on the basis of the 
clinical signs and results of laboratory 
examination. Nausea, vomiting, and 
neck stiffness developed, and the 
patient lost consciousness. Physical 
examination showed a positive Kernig 
sign and negative Brudzinski sign. 
The patient’s cerebrospinal ﬂ  uid 
sample was injected into chocolate 
agar, in which microbial growth was 
observed after 24 hours. The API NH 
system (bioMérieux, Marcy-Etoile, 
France) showed that the isolate was 
N. meningitidis. However, this strain 
could not be placed in a serogroup, 
even after speciﬁ  c antiserum (Remel, 
Lenexa, KS, USA) was used. No other 
disease with complement deﬁ  ciency 
was detected in the patient. The 
patient’s infection was treated with 
antimicrobial drugs, and he recovered 
completely.
We investigated this nonsero-
groupable  N. meningitidis strain by 
multilocus sequence typing (MLST), 
pulsed-ﬁ   eld gel electrophoresis 
(PFGE), and subtyping of the variable 
regions of the genes (porA, porB, and 
fetA) encoding the outer membrane 
proteins. MLST indicated that the 
fumC was a new allele with a new 
number 482. The allele numbers for 
abcZ,  adk, fumC,  gdh, pdhC, and 
pgm were 222, 3, 58, 386, 18, and 77, 
respectively. This strain was assigned 
a new sequence type number, ST7962.
Among the 44 complexes 
designed in the MLST database, 
ST7962 was most similar to the 
ST4821 complex with 3 identical 
loci. The PFGE pattern of this 
strain was compared with the PFGE 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011  569
1Current afﬁ  liation: Pﬁ  zer Inc., Hong Kong 
Special Administrative Region, People’s 
Republic of China. 